AU2010206549B2 - Use of pterosin compounds for treating diabetes and obesity - Google Patents

Use of pterosin compounds for treating diabetes and obesity Download PDF

Info

Publication number
AU2010206549B2
AU2010206549B2 AU2010206549A AU2010206549A AU2010206549B2 AU 2010206549 B2 AU2010206549 B2 AU 2010206549B2 AU 2010206549 A AU2010206549 A AU 2010206549A AU 2010206549 A AU2010206549 A AU 2010206549A AU 2010206549 B2 AU2010206549 B2 AU 2010206549B2
Authority
AU
Australia
Prior art keywords
compound
pterosin
compounds
mice
glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010206549A
Other languages
English (en)
Other versions
AU2010206549A9 (en
AU2010206549A1 (en
Inventor
Feng-Lin Hsu
Shing-Hwa Liu
Biing-Juan Uang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Tsing Hua University NTHU
National Taiwan University NTU
Taipei Medical University TMU
DCB USA LLC
Original Assignee
National Tsing Hua University NTHU
National Taiwan University NTU
Taipei Medical University TMU
DCB USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Tsing Hua University NTHU, National Taiwan University NTU, Taipei Medical University TMU, DCB USA LLC filed Critical National Tsing Hua University NTHU
Publication of AU2010206549A1 publication Critical patent/AU2010206549A1/en
Application granted granted Critical
Publication of AU2010206549A9 publication Critical patent/AU2010206549A9/en
Publication of AU2010206549B2 publication Critical patent/AU2010206549B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2010206549A 2009-01-26 2010-01-26 Use of pterosin compounds for treating diabetes and obesity Ceased AU2010206549B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14738209P 2009-01-26 2009-01-26
US61/147,382 2009-01-26
PCT/US2010/022129 WO2010085811A2 (en) 2009-01-26 2010-01-26 Use of pterosin compounds for treating diabetes and obesity

Publications (3)

Publication Number Publication Date
AU2010206549A1 AU2010206549A1 (en) 2011-08-11
AU2010206549A9 AU2010206549A9 (en) 2016-08-25
AU2010206549B2 true AU2010206549B2 (en) 2016-08-25

Family

ID=42354647

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010206549A Ceased AU2010206549B2 (en) 2009-01-26 2010-01-26 Use of pterosin compounds for treating diabetes and obesity

Country Status (10)

Country Link
US (1) US8633252B2 (enExample)
EP (1) EP2389171B1 (enExample)
JP (1) JP5640019B2 (enExample)
KR (1) KR101746867B1 (enExample)
CN (1) CN102333528B (enExample)
AU (1) AU2010206549B2 (enExample)
CA (1) CA2749931C (enExample)
NZ (1) NZ594236A (enExample)
TW (1) TWI522109B (enExample)
WO (1) WO2010085811A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105555287A (zh) * 2013-06-19 2016-05-04 捷通国际有限公司 用于支持体重管理的基于植物的己酮糖激酶抑制剂
CN106831386A (zh) * 2015-12-04 2017-06-13 江西中医药大学 新型蕨素类化合物在治疗糖尿病的应用
CN105878220B (zh) * 2016-04-21 2019-02-05 广州市爱菩新医药科技有限公司 倍半萜类化合物在制备防治高血脂药物中的应用
CN107232497A (zh) * 2017-06-01 2017-10-10 河北农业大学 一种具有降血脂功能的膨化食品及其制备方法
EP3639817B1 (en) * 2017-06-16 2024-10-09 Korpharm Co., Ltd. Compositions containing pterosin compound and derivatives thereof active ingredients for prevention or treatment of degenerative brain diseases
CN108576355B (zh) * 2018-03-27 2021-11-09 百色学院 一种蕨菜多糖含片及其制备方法
CN110156738B (zh) * 2019-06-26 2023-01-03 中北大学 一种伊鲁烷型倍半萜反应中间体及天然产物的全合成方法
KR102767836B1 (ko) * 2020-12-14 2025-02-14 주식회사 지에이치팜 프테로신 화합물 및 이의 유도체를 유효성분으로 포함하는 pka 관련 질환 예방 또는 치료용 약학적 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020256A1 (de) * 2001-08-31 2003-03-13 Aventis Pharma Deutschland Gmbh Verwendung von c2-substituierten indan-1-on-systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas
US20030134879A1 (en) * 2001-08-31 2003-07-17 Gerhard Jaehne Use of C2-substituted indan-1-ol systems for preparing medicaments for the prophylaxis or treatment of obesity
US20050075338A1 (en) * 2001-07-27 2005-04-07 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
US20060111445A1 (en) * 2003-01-13 2006-05-25 Nathalie Adje Novel carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia
US20080139599A1 (en) * 2005-01-14 2008-06-12 Michel Brunet Phenylbenzoic Acid Derivatives, Processes for the Preparation Thereof, Pharmaceutical Compositions Comprising Them, and Therapeutic Uses Thereof
US20090012093A1 (en) * 2002-11-08 2009-01-08 Kohji Fukatsu Receptor Function Regulator

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745104A (en) * 1985-04-15 1988-05-17 The Regents Of The University Of California Pseudopterosin and synthetic derivatives thereof
US4849410A (en) * 1985-04-15 1989-07-18 The Regents Of The University Of California Pseudopterosin and synthetic derivatives thereof
JPS63146839A (ja) 1986-12-11 1988-06-18 Toa Nenryo Kogyo Kk プテロシン系化合物を含んで成る制癌剤
JPH02237932A (ja) * 1989-03-10 1990-09-20 Yokichi Mochizuki 結石等の治療剤
US5439936A (en) * 1989-10-03 1995-08-08 The Regents Of The University Of California Method of treating certain tumors using illudin analogs
CA2135474C (en) * 1993-04-07 1998-11-10 Shingo Yano Thiazolidine derivatives and pharmaceutical compositions containing the same
WO1998025907A1 (en) 1996-12-12 1998-06-18 Banyu Pharmaceutical Co., Ltd. Pyrazole derivatives
FR2777566B1 (fr) * 1998-04-15 2003-02-21 Synthelabo Derives d'azacycloalcanes, leur preparation et leur application en therapeutique
SK288217B6 (sk) * 2001-01-26 2014-08-05 Merck Sharp & Dohme Corp. Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie
US6797287B2 (en) * 2001-09-25 2004-09-28 Pharmachem Laboratories, Inc. Phaseolamin compositions and methods for using the same
CN100544715C (zh) * 2002-04-30 2009-09-30 尤尼根制药公司 作为治疗剂的包含无取代b环类黄酮和黄烷混合物的组合物
AU2003287965A1 (en) * 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
CA2516710A1 (en) * 2003-02-26 2004-09-10 Unigen Pharmaceuticals, Inc. Formulation for use in the prevention and treatment of carbohydrate induced diseases and conditions
JP2007510651A (ja) * 2003-11-04 2007-04-26 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としての縮合フェニルアラニン誘導体
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
UA92150C2 (ru) * 2004-06-04 2010-10-11 Арена Фармасьютикалз, Инк. Замещенные производные арила и гетероарила как модуляторы метаболизма и для профилактики и лечения связанных с ним расстройств
JP2008522972A (ja) * 2004-12-06 2008-07-03 レリアント ファーマスーティカルズ インコーポレイテッド 脂肪酸エステルを有する安定性フェノフィブラート組成物
CA2595835A1 (en) * 2005-02-05 2006-08-10 Astrazeneca Ab Chemical compounds
AU2006291234A1 (en) * 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
US20080200458A1 (en) * 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050075338A1 (en) * 2001-07-27 2005-04-07 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
WO2003020256A1 (de) * 2001-08-31 2003-03-13 Aventis Pharma Deutschland Gmbh Verwendung von c2-substituierten indan-1-on-systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas
US20030134879A1 (en) * 2001-08-31 2003-07-17 Gerhard Jaehne Use of C2-substituted indan-1-ol systems for preparing medicaments for the prophylaxis or treatment of obesity
US20090012093A1 (en) * 2002-11-08 2009-01-08 Kohji Fukatsu Receptor Function Regulator
US20060111445A1 (en) * 2003-01-13 2006-05-25 Nathalie Adje Novel carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia
US20080139599A1 (en) * 2005-01-14 2008-06-12 Michel Brunet Phenylbenzoic Acid Derivatives, Processes for the Preparation Thereof, Pharmaceutical Compositions Comprising Them, and Therapeutic Uses Thereof

Also Published As

Publication number Publication date
WO2010085811A2 (en) 2010-07-29
EP2389171A4 (en) 2012-10-10
AU2010206549A9 (en) 2016-08-25
JP2012515801A (ja) 2012-07-12
TWI522109B (zh) 2016-02-21
CN102333528A (zh) 2012-01-25
KR20110125642A (ko) 2011-11-21
NZ594236A (en) 2014-08-29
CA2749931A1 (en) 2010-07-29
EP2389171B1 (en) 2016-03-30
US20100190732A1 (en) 2010-07-29
US8633252B2 (en) 2014-01-21
CA2749931C (en) 2018-03-06
EP2389171A2 (en) 2011-11-30
CN102333528B (zh) 2013-12-18
KR101746867B1 (ko) 2017-06-14
WO2010085811A9 (en) 2010-11-04
AU2010206549A1 (en) 2011-08-11
TW201039836A (en) 2010-11-16
JP5640019B2 (ja) 2014-12-10

Similar Documents

Publication Publication Date Title
AU2010206549B2 (en) Use of pterosin compounds for treating diabetes and obesity
Alwan et al. Onco-immunity and therapeutic application of amygdalin: A review
US20170002039A1 (en) A Pentacyclic Triterpenoid Compound with Modified Structure and Preparation Method and Use Thereof
BR112017005416B1 (pt) composição farmacológica para uso em medicamento para tratar ou prevenir doenças neurológicas degenerativas contendo como ingrediente ativo extrato de mistura de casca da raiz de peônia da montanha, raiz de angelica dahurica e raiz de bupleurum ou fragmentos dos mesmos
KR20140102599A (ko) 뇌암 치료를 위한 방법 및 조성물
CN103804442B (zh) 黄酮醇衍生物及其医药用途
CN103585166B (zh) 黄醇酮衍生物的医药用途
CN103420805B (zh) 天麻中具有神经细胞保护活性的多聚苄类衍生物
CN102688489A (zh) 含有雷公藤甲素及雷公藤甲素类衍生物和Bcl-2抑制剂的药物组合物及其应用
CN105777854A (zh) 硫酸依替米星的药物组合物及其在生物医药中的应用
CN103908567B (zh) 一种用于治疗糖尿病痛性神经病变的复方制剂及其应用
US10064908B2 (en) Method for preventing, improving or treating liver disease
CN104546875B (zh) 三萜皂苷衍生物及其医药用途
CN106176711A (zh) 包含类黄酮化合物组合物的药物及其应用
CN114748472B (zh) 丝裂霉素c在制备抗抑郁药物中的应用
CN110882315A (zh) 一种预防结肠癌的地榆提取物及其制备方法与应用
CN114053283B (zh) 3β,23-O-异丙叉基羟基白桦酸在制备治疗非酒精性脂肪性肝炎药物中的应用
CN103221044A (zh) Xanthanodien抗癌症的治疗用途
KR102113563B1 (ko) 하이드란제놀을 유효성분으로 하는 근육 질환 예방 및 치료, 근기능 개선, 또는 운동수행능력 향상용 조성물
CN120053556A (zh) 百合莲子组合在改善肥胖与2型糖尿病中的应用
WO2014187186A1 (zh) 含有苦参素和甘草酸的药物组合物制备治疗银屑病的应用
KR20130141420A (ko) 인삼 열매 추출물을 함유하는 혈행촉진, 혈관신생촉진, 및 허혈성 심질환 치료용 조성물
CN101780125A (zh) 急性子抗类风湿性关节炎的医药用途
US20100197803A1 (en) Method for obtaining a sequoyitol-containing extract from a plant of the genus of trifolium, leguminosae or ginkoaceae and uses thereof
CN105535019A (zh) 一种治疗肝癌的含银杏酚药物组合物

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired